CN
CN
Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in China
November 07, 2019

NEW YORK November 7, 2019 – Kadmon Holdings, Inc. (NYSE: KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and commercialize KD025 for the treatment of graft-versus-host disease (GVHD) in the People’s Republic of China.